KR20240074779A - 약학적 조성물 및 이의 용도 - Google Patents

약학적 조성물 및 이의 용도 Download PDF

Info

Publication number
KR20240074779A
KR20240074779A KR1020247011293A KR20247011293A KR20240074779A KR 20240074779 A KR20240074779 A KR 20240074779A KR 1020247011293 A KR1020247011293 A KR 1020247011293A KR 20247011293 A KR20247011293 A KR 20247011293A KR 20240074779 A KR20240074779 A KR 20240074779A
Authority
KR
South Korea
Prior art keywords
permonetinib
pharmaceutically acceptable
acceptable salt
egfr
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247011293A
Other languages
English (en)
Korean (ko)
Inventor
후이빙 루오
칭 리
Original Assignee
상하이 알리스트 파마슈티컬즈 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 알리스트 파마슈티컬즈 씨오., 엘티디. filed Critical 상하이 알리스트 파마슈티컬즈 씨오., 엘티디.
Publication of KR20240074779A publication Critical patent/KR20240074779A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247011293A 2021-09-10 2022-04-11 약학적 조성물 및 이의 용도 Pending KR20240074779A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/117692 2021-09-10
PCT/CN2021/117692 WO2023035223A1 (zh) 2021-09-10 2021-09-10 药物组合物及其用途
PCT/CN2022/086053 WO2023035611A1 (en) 2021-09-10 2022-04-11 Pharmaceutical composition and use thereof

Publications (1)

Publication Number Publication Date
KR20240074779A true KR20240074779A (ko) 2024-05-28

Family

ID=85507161

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247011293A Pending KR20240074779A (ko) 2021-09-10 2022-04-11 약학적 조성물 및 이의 용도

Country Status (10)

Country Link
US (1) US20240366600A1 (cg-RX-API-DMAC10.html)
EP (1) EP4398909A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024533423A (cg-RX-API-DMAC10.html)
KR (1) KR20240074779A (cg-RX-API-DMAC10.html)
CN (1) CN117957000A (cg-RX-API-DMAC10.html)
AU (1) AU2022341942A1 (cg-RX-API-DMAC10.html)
CA (1) CA3231192A1 (cg-RX-API-DMAC10.html)
IL (1) IL311331A (cg-RX-API-DMAC10.html)
MX (1) MX2024002822A (cg-RX-API-DMAC10.html)
WO (2) WO2023035223A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159062A (zh) * 2021-11-24 2023-05-26 上海艾力斯医药科技股份有限公司 药物组合物及其用途
CN119278041A (zh) * 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
CN116478138A (zh) * 2023-04-21 2023-07-25 江苏艾力斯生物医药有限公司 一种甲磺酸伏美替尼原料药的结晶方法
CN116893086A (zh) * 2023-04-28 2023-10-17 江苏艾力斯生物医药有限公司 一种靶向药甲磺酸伏美替尼片的模拟片及其制备方法
CN117547536A (zh) * 2023-11-15 2024-02-13 江苏艾力斯生物医药有限公司 一种药物组合物、其制备方法及应用
CN118576597B (zh) * 2024-05-27 2026-08-04 厦门大学附属第一医院 一种联合用药物组合物及其在制备预防、改善或治疗tp53突变双重打击淋巴瘤的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
CN107163027B (zh) * 2016-03-07 2019-11-05 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
CN107163026B (zh) * 2016-03-07 2019-07-02 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物的盐及其制备方法和应用

Also Published As

Publication number Publication date
CN117957000A (zh) 2024-04-30
EP4398909A4 (en) 2025-08-13
AU2022341942A1 (en) 2024-05-02
IL311331A (en) 2024-05-01
CA3231192A1 (en) 2023-03-16
US20240366600A1 (en) 2024-11-07
EP4398909A1 (en) 2024-07-17
MX2024002822A (es) 2024-05-03
JP2024533423A (ja) 2024-09-12
WO2023035223A1 (zh) 2023-03-16
WO2023035611A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
US20240366600A1 (en) Pharmaceutical compositions and use thereof
US20250017927A1 (en) Pharmaceutical composition and use thereof
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN113710658A (zh) 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐
US20220193066A1 (en) Quinoline derivative used for combination treatment of small cell lung cancer
CN116723858A (zh) 图卡替尼联合曲妥珠单抗、紫杉烷和vegfr-2拮抗剂治疗her2阳性癌症的方法
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
WO2024061203A1 (en) Pharmaceutical composition and use thereof
JP7571053B2 (ja) 軟部肉腫の併用療法用キノリン誘導体
CN113116895A (zh) 用于治疗神经母细胞瘤的喹啉衍生物
HK40110967A (en) Pharmaceutical composition and use thereof
HK40116696A (en) Pharmaceutical composition and use thereof
HK40065487A (en) Quinoline derivative used for soft tissue sarcoma combination therapy
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
HK40072142A (en) Quinoline derivative used for combination treatment of small cell lung cancer
CN119818513A (zh) 治疗儿科患者的癌症的方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240404

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250408

Comment text: Request for Examination of Application